# OnCo record midostaurin (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/midostaurin/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "midostaurin" ;
  schema:name "Midostaurin"@en ;
  schema:description "The first drug to improve survival in FLT3-mutated AML, added to standard chemotherapy: median survival went from about two years to more than six."@en ;
  schema:url <https://onco.cc/drugs/midostaurin/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Midostaurin> ;
  owl:sameAs <http://www.wikidata.org/entity/Q6842945> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Midostaurin> ;
  onco:status "approved" ;
  onco:modality "Small-molecule multikinase inhibitor (FLT3)" ;
  schema:alternateName "Rydapt" ;
  onco:approval "US 2017: Newly diagnosed FLT3-mutated AML with 7+3 and consolidation; advanced systemic mastocytosis" ;
  onco:related <https://onco.cc/biomarkers/flt3-itd/>, <https://onco.cc/biomarkers/flt3-tkd/> ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/systemic-mastocytosis/>, <https://onco.cc/cancers/aml-flt3/>, <https://onco.cc/cancers/advanced-systemic-mastocytosis/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/flt3/>, <https://onco.cc/targets/kit/> ;
  onco:companies <https://onco.cc/companies/novartis/> ;
  onco:trials <https://onco.cc/trials/ratify/>, <https://onco.cc/trials/nct03591510/> .